References
- Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult. Scler. 18( 2 Suppl.), 7–15 (2012).
- Oreja-Guevara C, González D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int. J. Neurosci. 123(6), 400–408 (2013).
- Fernández O, Baumstarck-Barrau K, Simeoni M-C, Auquier P on behalf of the MusiQoL study group. Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires. Mult. Scler. 17(10), 1238–1249 (2011).
- Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 97(10), 671–676 (2004).
- Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10(5), 589–595 (2004).
- Bensmail D, Vermersch P. Epidemiology and clinical assessment of spasticity in multiple sclerosis. [Article in French]. Rev. Neurol. (Paris) 168( Suppl. 3), S45–S50 (2012).
- Berger T. Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Rev. Neurother. 13( 3 Suppl. 1), 3–7 (2013).
- Arroyo R, Vila C, Asensio D, Covas A, Clissold S on behalf of the “5E” study group. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study. Expert Rev. Pharmacoecon. Outcomes Res. 11(2), 205–213 (2011).
- Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin. Ther. 30(5), 974–985 (2008).
- Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int. J. Neurosci. (2013) ( Epub ahead of print).